Candel Therapeutics, INC 10-Q quarterly reports

Candel Therapeutics announced positive topline data from its Phase 3 prostate cancer trial and updated data for NSCLC and pancreatic cancer, while also detailing its financial position and ongoing capital requirements.

Candel Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing progress in its clinical-stage biopharmaceutical development and financial performance.

Candel Therapeutics reports positive clinical trial data for CAN-2409 in prostate and NSCLC, secures new $130M debt facility, and extends cash runway into Q1 2027.

Candel Therapeutics, a clinical-stage biopharmaceutical company, reported net income for the first six months of 2025, driven by positive clinical trial results for its lead cancer immunotherapies and a significant warrant revaluation.

Candel Therapeutics reports a net income of $7.4 million for Q1 2025, driven by a change in the fair value of warrant liability, while continuing to advance its clinical-stage viral immunotherapies.

Candel Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical trials and financial challenges.

Candel Therapeutics reports a net loss of $30.5 million for the first half of 2024, while highlighting positive clinical data for its lead product candidates.

Candel Therapeutics reports a net loss of $8.2 million for the first quarter of 2024, with ongoing clinical trials and a focus on the development of CAN-3110 and the enLIGHTEN Discovery Platform.